HTA of the Innovative Medicines in Germany

The Market Access of the innovative medicines, is monitored by both Regulators and Payers. To assess the new drugs; if they deliver a fair value for money. The remarkable recent discrepancies between both parties' requirements during the market entry process, represent a financial threat on the Pharmaceutical industry. The evolving restrictions would alter the industry motive to invest in Research and Development. Consequently, patients will not receive the appropriate medicines to win their battles against the developed ailments which may then contribute to a public health alarm.

Autorentext

Je suis un professionnel de l'industrie pharmaceutique et j'ai 10 ans d'expérience dans des géants internationaux de l'industrie pharmaceutique. J'ai travaillé pour Pfizer, Johnson & Johnson, Boehringer Ingelheim et Sanofi. Jusqu'à récemment, j'étais titulaire d'une maîtrise en pharmaco-économie internationale et en économie de la santé délivrée par l'université de Cardiff, au Royaume-Uni.